Non-selective beta-blockers and the incidence of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis
Background: Hepatocellular carcinoma (HCC) is a serious complication of cirrhosis. Currently, non-selective beta-blockers (NSBBs) are commonly used to treat portal hypertension in patients with cirrhosis. The latest research shows that NSBBs can induce apoptosis and S-phase arrest in liver cancer ce...
Main Authors: | Xinyi He, Zimo Zhao, Xi Jiang, Yan Sun |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1216059/full |
Similar Items
-
Beta-blockers in patients with liver cirrhosis: Pragmatism or perfection?
by: Tilman Sauerbruch, et al.
Published: (2023-01-01) -
Tumor Recurrence in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: Portal Hypertension as an Indicator of Recurrence of Hepatocellular Carcinoma
by: Seong Won Jang, et al.
Published: (2018-11-01) -
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients
by: Yu Jun Wong, et al.
Published: (2023-01-01) -
Immune changes over time and survival in patients with cirrhosis treated with non-selective beta-blockers: A prospective longitudinal study
by: Susana Almenara, et al.
Published: (2023-07-01) -
Role of the spleen in patients with liver cancer and cirrhosis
by: CHANG Jessica, CHEN Xuxiao, CHEN Yongjun
Published: (2023-07-01)